Mallinckrodt Completes Financial Restructuring and Irish Examinership Proceedings and Emerges From Chapter 11
Retrieved on:
Tuesday, November 14, 2023
EBITDA, Food and Drug Administration, Corporation, Independent monitoring board, Food, New Board, LLP, Chairperson, Silver Point Capital, Patient, FDA, Specialty, Trust, Latham & Watkins, Growth, Guggenheim Partners, The Company, Adrenocorticotropic hormone (medication), AlixPartners, Alpha Metallurgical Resources, Pharmaceutical industry, Management, Mallinckrodt, Ajman Specialty General Hospital
DUBLIN, Nov. 14, 2023 /PRNewswire/ -- Mallinckrodt plc ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today announced that it has completed its financial restructuring, emerged from Chapter 11 following an expedited court-supervised process and completed the Irish Examinership Proceedings.
Key Points:
- DUBLIN, Nov. 14, 2023 /PRNewswire/ -- Mallinckrodt plc ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today announced that it has completed its financial restructuring, emerged from Chapter 11 following an expedited court-supervised process and completed the Irish Examinership Proceedings.
- Supported by an enhanced capital structure, Mallinckrodt will continue to focus on advancing its business across its portfolio and executing on recent and planned product launches.
- The Company's Specialty Generics segment benefits from vertical integration and high-quality U.S.-based manufacturing plants that have supported strong growth.
- Latham & Watkins LLP, Wachtell, Lipton, Rosen & Katz, Arthur Cox LLP, Richards, Layton & Finger PA, and Hogan Lovells US LLP served as Mallinckrodt's counsel.